New Unified Framework Aims to Standardize Stroke Core Size Terminology

Stroke remains one of the leading causes of death and disability worldwide, and the window for effective treatment is narrow. Central to acute stroke management is accurately characterizing the ischemic core — the region of the brain where blood supply has been so severely reduced that neurons have already died or are beyond rescue. Decisions about whether to perform mechanical thrombectomy or administer thrombolytics often hinge on the size of this core, making precise and consistent measurement critical.

Despite its clinical importance, the field has lacked a standardized vocabulary for describing ischemic core size. Different research groups, imaging protocols, and clinical guidelines have used varying terms interchangeably, creating confusion when comparing results across studies or applying findings to patient care. This terminological fragmentation has likely impaired the ability to synthesize evidence and optimize patient selection criteria.

In this viewpoint article published in JAMA Neurology, Dr. Jeffrey Saver of UCLA's Comprehensive Stroke Center proposes a new, unified terminology framework specifically designed to resolve these inconsistencies. The framework systematically defines categories of ischemic core size in a coherent, clinically meaningful way, providing common language that clinicians and researchers can adopt across settings.

The implications of such a framework are broad. Standardized terminology could improve communication between neurologists, radiologists, and interventionalists at the point of care. It could also enhance the design and interpretation of clinical trials by ensuring that patient populations are described and stratified consistently. Over time, adoption of unified language may facilitate meta-analyses and registry studies that require pooling data across sites.

It is important to note that this article is a viewpoint — an expert opinion and conceptual proposal — rather than an original data-driven study. The framework's real-world utility will ultimately depend on uptake by the clinical and research community and validation through prospective use in trials and practice.